School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, Republic of Korea.
Braz J Infect Dis. 2013 Jan-Feb;17(1):74-81. doi: 10.1016/j.bjid.2012.10.009. Epub 2013 Jan 1.
Tuberculosis infection is a serious human health threat and the early 21st century has seen a remarkable increase in global tuberculosis activity. The pathogen responsible for tuberculosis is Mycobacterium tuberculosis, which adopts diverse strategies in order to survive in a variety of host lesions. These survival mechanisms make the pathogen resistant to currently available drugs, a major contributing factor in the failure to control the spread of tuberculosis. Multiple drugs are available for clinical use and several potential compounds are being screened, synthesized, or evaluated in preclinical or clinical studies. Lasting and effective achievements in the development of anti-tuberculosis drugs will depend largely on the proper understanding of the complex interactions between the pathogen and its human host. Ample evidence exists to explain the characteristics of tuberculosis. In this study, we highlighted the challenges for the development of novel drugs with potent bacteriostatic or bactericidal activity, which reduce the minimum time required to cure tuberculosis infection.
结核病感染是严重的人类健康威胁，21 世纪初全球结核病活动显著增加。引起结核病的病原体是结核分枝杆菌，它采用多种策略在宿主的各种病变中存活。这些生存机制使病原体对现有药物产生耐药性，是导致结核病传播控制失败的一个主要因素。有多种药物可供临床使用，并且正在对几种潜在的化合物进行筛选、合成或临床前或临床研究评估。在抗结核药物开发方面取得持久有效的成果，在很大程度上取决于对病原体与其人类宿主之间复杂相互作用的正确理解。有充分的证据可以解释结核病的特征。在这项研究中，我们强调了开发具有强大抑菌或杀菌活性的新型药物所面临的挑战，这些药物可以减少治愈结核病感染所需的最短时间。
